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PDC). The outcome was adherence to AH drugs in the 6-month post-index period.
Logistic regression analysis was conducted to explore the impact of CVD hospital-
izations on changes in adherence to AH drugs. RESULTS: There were 1332 patients
with AH drugs. Patients with a CVD hospitalizationwere 2.9 times (95% Confidence
Interval: 2.1-3.9) more likely to be adherent in the 6-month post-index period com-
pared to control patients. Among patients with a CVD hospitalization, the propor-
tion of patients who were non-adherent to AH drugs in the 6-month post-index
period was 30.6%. CONCLUSIONS: Patient adherence to AH drugs improved after a
CVD hospitalization, but there was still a substantial proportion of patients who
were non-adherent after that hospitalization. Counseling patients on medication
adherence during their hospitalizationmay be an effective way for improving their
adherence following discharge.
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OBJECTIVES: To estimate patient adherence with once-a-day (QD) vs. twice-a-day
(BID) chronic medications following hospital discharge for ACS. METHODS: A ret-
rospective cohort study of patients discharged between 1/1/2007 and 4/30/2009
with an ACS diagnosis was performed using a large hospital and pharmacy claims
dataset. Two chronic medications dispensed for QD and BID utilization, carvedilol
andmetformin, were analyzed for adherencemeasures [persistency, days on ther-
apy, compliance (medication possession ratio, MPR), total # of dispensed prescrip-
tions, gap (days) between refills] over a 12 month post-index period. Included pa-
tients had first dispensed prescription of carvedilol or metformin within 60 days of
discharge (index prescription) and had Rx activity for any drug  12 months post-
index. Persistence was defined as percentage of patients without a therapy lapse
of  30 days from last dispensed day’s supply. RESULTS: Persistency with carve-
dilol QD vs. BID (N168 vs. 2086) at 6 months was 44.0% vs 43.7% and at 12 months
was 24.4% vs. 25.5%. Persistency with metformin QD vs. BID (N136 vs. 614) at 6
months was 50.7% vs 53.7% and at 12 months was 28.7 vs. 35.0%. The average days
on therapy for carvedilol QD vs. BID at 6 months was 120.5 vs. 121.9 and at 12
months was 196.7 vs. 203.0. Average days on therapy for metformin QD vs. BID at 6
monthswas 123.6 vs. 136.2 and at 12monthswas 206.1 vs. 237.7. Compliance (MPR)
with QD vs. BID carvedilol at 12months was 84.2% vs 80.7% and for metformin was
77.6% vs 81.6%. Additional adherence metrics were consistent for QD vs. BID
dosing. CONCLUSIONS: In ACS patients, no clinically meaningful differences on
adherence measures were observed between QD versus BID dosing formulations
over a 12 month follow-up period. Results indicate potential opportunities to im-
prove persistency with chronic therapies in ACS patients.
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OBJECTIVES: Justification for the Use of Statins in Prevention: an Intervention Trial
Evaluating Rosuvastatin (JUPITER) demonstrated a statin benefit for primary pre-
vention. However, real-world patientsmay not exhibit medication persistence and
adherence seen in the trial. We described persistence and adherence of first-time
statin users. METHODS: A 10% random sample of the IMS LifeLink Health Plan
Claims Database was used to obtain prescription claims records for adult (18
years) first-time statin users with continuous health plan eligibility 12 months
prior and 32 months after the index statin prescription between July 1, 1997 and
December 31, 2008. Persistence and adherence were measured during the 24
months after statin initiation. Patients were persistent if gaps in statin use did not
exceed 180 consecutive days. Adherence was measured as the medication posses-
sion ratio (MPR) during the period of persistence. Persistence groups were catego-
rized as ‘short’ (9 months), ‘intermediate’ (9-16 months) and ‘long’ (17months)
and compared using ANOVA. RESULTS: Among 26,530 new statin users, the mean
length of persistence was 17months. The proportions in each persistence category
were: 21% ‘short’, 12% ‘intermediate’ and 68% ‘long’. 32% were persistent for 24
months or more, as compared to 75% of JUPITER patients taking medication after
the median 1.9 year study period. Mean MPR of the ‘intermediate’ and ‘short’ per-
sistence categories were similar (0.70 vs. 0.69, P.15), but lower than the overall
mean MPR of 0.80. Mean MPR was greatest in the ‘long’ persistence category (0.85,
P.0001) and was higher than the overall mean MPR. CONCLUSIONS: Persistence
and adherence measure two different but critical concepts: the length of time
patients use statins and their adherence to the statin regimen during that period,
which we found to vary. Extrapolating the primary prevention benefits of statins
must account for both measures, as they differ from clinical trials to practice.
PCV66
ADHERENCE RATES AMONG HEALTH PLAN MEMBERS STARTING GENERIC
VERSUS BRAND STATIN THERAPY
Chen Q1, Kachur SG2, Fatodu H2, Garber H2
1Johns Hopkins Bloomsberg School of Public Health, Baltimore, MD, USA, 2Johns Hopkins
HealthCare, Glen Burnie, MD, USA
OBJECTIVES: Several studies have demonstrated that higher patient out-of pocket
cost may result in lower medication adherence. The purpose of this study was to
measure Medication Possession Ratio (MPR) among patients newly-prescribed a
brand or generic statin medication in a managed Medicaid plan and a commercial
health plan. METHODS: We conducted a retrospective analysis using pharmacy
claims data to identify patients who were new to statin treatment (no pharmacy
claim for a lipid-lowering medication in the previous 12 months). Patients were
categorized based on their index medication. We used a Robust linear regression
model to determine predictors of adherence. RESULTS: A total of 738 commercial
patients and 2175 Medicaid patients were included. Sixty percent of Medicaid pa-
tients and 49% of commercial patients initiated therapywith a genericmedication.
Average patient out-of-pocket cost for commercial plan patients was $9/month for
generic and $15/month for brand. Medicaid patients had no copayment for generic
or brand medications. In the commercial plan, there was no significant difference
in MPR between patients who initiated therapy with generic or brand statins (MPR
0.75 vs. 0.73, respectively). In the Medicaid plan, MPR was significantly higher
among patients who started on generic medications (0.69 vs. 0.63). In robust linear
regression, MPR was significantly related to age, number of comorbidities and ge-
neric use. After we adjusted MPR for age and comorbidities, MPR remained signif-
icantly higher in the Medicaid generic group. CONCLUSIONS: Medicaid patients
prescribed a generic statin as initial therapy were more adherent than those pre-
scribed a brand, despite having no copayment for generic or brand medications.
This differencewas not present among commercial plan patientswho had a higher
cost share for brandmedications. This suggests that additional research is needed
to identify non-financial barriers to adherence.
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OBJECTIVES: To examine statin adherence and persistence among patients receiv-
ing treatment for secondary prevention of coronary heart disease (CHD) at US
Military Treatment Facilities (MTF) within the Department of Defense (DoD).
METHODS: Retrospective cohort study utilizing the DoD Military Health System
database to examine 21,053 TRICARE beneficiaries between 18-75 years of age,
receiving medical services for a primary CHD event at an MTF between January 1,
2004 and December 31, 2008. Drug adherence was measured using the Medication
Possession Ratio (MPR) at 6, 12 and 18 months. Persistence was measured as dura-
tion of statin-therapy based on35-day refill gap. Covariates included age, gender,
comorbidities, drug-switching and dosage titration. Logistic regression was con-
ducted to assess predictors of adherence [95% Confidence-Intervals]. RESULTS:
The CHD cohort (N21,053) was 74% male with a mean age of 57.4(SD8.8) years.
Overall mean MPR was 89%(SD22) at month six (M6), 84%(SD25) at 12-months
(M12), and 81%(SD26.4) after 18-months (M18). Approximately 80% of patients
were adherent (MPR80%)with statin-therapy atM6which declined to 71% atM12,
and 69% at the end of M18 (p.001). Older male patients with hyperlipidemia were
more adherent. Adjusting for covariates, patients were more likely to be adherent
at M6, M12, and M18 that switched statins (OR1.87[1.65-2.13],1.3[1.24-1.46], and
1.07[1.00-1.15]) or had at least one titration adjustment (OR2.99[2.62-3.40],1.86
[1.72-2.01], and 1.54[1.44-1.65]) compared to patients with no therapeutic adjust-
ments. Overall mean persistence to statins was 322 days. Patients experiencing
35-day refill gap increased from 34% to 53% to 63% at 6, 12, and 18-months
respectively. CONCLUSIONS: This study showed statin adherencewas high among
DoD patients receiving medical care at MTFs for secondary prevention of CHD
during the first 6-months. Adherence and persistence, however, declined bymonth
12. Improved patient adherence was associated with closer monitoring of pre-
scribed therapy, as seen among patients who were titrated or switched statins.
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OBJECTIVES: A recent study by our team indicated that approximately 13% of
prescribed venous thromboembolism (VTE) prophylactic doses are not adminis-
tered. The goal of this study was to determine documented reasons and describe
the distribution patterns for non-administered VTE prophylaxis doses.METHODS:
We conducted a retrospective review of electronic medication administration re-
cords using our computerized physician order entry system. The study included
hospitalized patients aged 18 years or older who were ordered pharmacologic VTE
prophylaxis from December 1, 2007 through June 30, 2008. RESULTS: A total of
108,533 VTE prophylaxis doses were ordered for 8,607 patients. 12.8% of ordered
doses were not administered. Non-administration rates varied by patient floor
from 4.8% to 33.9%. Approximately 53% of doses that were not administered (6.8%
of all doses) were documented as patient refusal – the most common documented
reason for non-administration of VTE prophylaxis by a widemargin. Patient refus-
als varied greatly by nursing unit, ranging from less than 1% to 19% of ordered
doses. Patient refusals were highly concentrated on certain nursing units; 5 nurs-
ing units accounted for two-thirds of all refused doses. A small number of patients
accounted for the vastmajority of refused doses; 11% of patients who refusedmore
than 1 dose accounted for nearly 87% of all refused doses. CONCLUSIONS: Patient
A44 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 – A 2 1 4
refusal of VTE prophylaxis doses is the most common documented reason these
doses are not administered. A small number of patients and nursing units account
for a vast majority of refused doses. We have initiated a mixed-methods investi-
gation to determine what patient, nursing unit, and culture of care-level factors
may explain refusal of these doses.
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IMPACT OF COMMUNITY PHARMACIST-LED COUNSELING ON IMPROVING
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OBJECTIVES: To assess the impact of pharmacist-led face-to-face counseling on
prescription first refill rate in patients who are new to statins or thyroid
medications. METHODS: A retrospective pre-post with case-control cohort study
design was employed. In May 2010, two community pharmacies implemented
face-to-face counseling by trained pharmacists at the site of care when patients
initially filled their statin or thyroid prescriptions. Patients’ first refill rate, defined
as percentage of patients who refilled their prescriptions within a two-week’s pe-
riod after exhaustion of their initial fill, was assessed as the primary outcome
measure. Similar computations were performed for patients’ who filled their study
medications at the two stores, 12-months prior to the intervention program. Addi-
tionally, two control pharmacy stores were selected based on pharmacy type, op-
erational years of stores, prescription volume, and corresponding population char-
acteristics. Refill rates in the pre and post-periods were also computed for control
stores. A chi-square test was performed to investigate the relationship between
face-to-face intervention and patients’ first refill rate. RESULTS: Test stores that
implemented face-to-face counseling, conducted interventions on 81 new to ther-
apy patients in the post period, while a total of 76 (new to therapy patients) were
included in the pre-period. A total of 73 and 81 new to therapy patients were
selected from control stores in the pre and post-period respectively. For test stores,
chi-square analyses showed a significant increase in the refill rates in the post-
period as compared to the pre-period (Pre-period: 55.7% Vs Post-period: 70.4%
p0.01), whereas control stores did not show any significant increase across two
periods (Pre-period: 56.2% Vs Post-period: 61.7%, p0.05). CONCLUSIONS: Pharma-
cist-led face-to-face counseling had a positive impact on patient’s refill behavior.
The study showed an early impact of the program; additional larger pilot studies
and longer follow-up period are needed to better understand the full benefit of the
program.
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OBJECTIVES: To measure and compare the extent of medication compliance in
elderly and geriatric hypertensive cohorts. To evaluate the role of illness percep-
tions and investigate how medication beliefs and dimensions of illness percep-
tions, might impact medication compliance outcome in hypertension.METHODS:
A cross-sectional research design, utilizing convenience sampling strategies and
self-administered surveys of elderly hypertensive residents living inNewYork City
senior care centers (N117).Medication compliancewasmeasured usingMorisky’s
test; medication beliefs were measured using Beliefs about Medication Question-
naire (BMQ), and illness perceptions using Brief Illness Perceptions Questionnaire
(BIPQ). RESULTS:MajoriMajority of the population was white (75%). There were no
significant differences observed demographically between the elderly (55-65 years)
and geriatric (65 years) samples except with respect to college education (53% vs.
47%). About 46% of the elderly sample was noncompliant with hypertension med-
ications, compared to 63%whowere 65 years and older (geriatric). BIPQ component
scores correlated positively with medication compliance score across both elderly
and geriatric samples (r 0.134; p0.496 and r 0.447; p0.000, respectively). The
score on Specific Necessity Beliefs dimension associated positively with Morisky’s
Test score across both the cohorts (r0.027, p0.892 and r0.297; p0.020),
whereas General Harm and General Overuse Beliefs about medication correlated
negatively with medication compliance. A majority of the participants rank-or-
dered stress as the number one cause of their illness (49.1%), followed by ‘lifestyle’
(43.8%) and ‘hereditary factors’ (7.1%). CONCLUSIONS:Medication noncompliance
seems to worsen with an increase in age. Stronger necessity beliefs and more
favorable perceptions about the illness are observed in geriatrics compared to el-
derly. The study underscores the importance of incorporating patient perceptions
about illness and medication beliefs into disease management frameworks that
seek to build medication compliance in hypertension.
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OBJECTIVES: To examine patterns of medication adherence and persistence with
antihypertensive or statin therapies among uninsured working-adults enrolled in
the Texas DMIE Study. METHODS: This study was a randomized controlled trial
(RCT) conducted to assess the effects of an intervention (i.e., improved medical
services and subsidized drug-copay) among uninsured working-adult participants
age 21-65 years, receiving medical services in the Harris County Health District.
Cardiovascular medication adherence and persistence were measured separately
for participants prescribed either statin or antihypertensive (i.e.,angiotensin-con-
verting-enzyme-inhibitor or angiotensin-receptor-blocker) therapy during an 18-
month period. Medication adherence was calculated as the proportion of days
covered (PDC). Participants were “adherent” when PDC 80%. Persistence was
measured as a 35-day gap between drug refills. Logistic regression and cox pro-
portional hazards models evaluated potential predictors of adherence and
persistence. RESULTS: For participants on statin therapy (N449), a higher mean
PDC (p0.01) was observed in the intervention cohort (0.61[SD0.27]) versus
control (0.51[SD.30]). Switching statins and titration adjustments were signif-
icant predictors of adherence. Adjusting for covariates, the intervention
(OR1.28[CI95%,1.01,2.68]) wasmore likely to be adherent to statins versus control.
Mean persistence with statins in the intervention was 230-days compared to 171-
days for control group participants. The intervention was less likely to experience
a refill gap (OR0.69[CI 95%,0.51,0.92]) versus control. For antihypertensive drugs
(N636), mean PDC in the intervention was 0.65 (SD0.27) versus 0.60 ((SD0.28)
for control (p0.02). Predictors of adherence included race/ethnicity, polyphar-
macy, and depression. The intervention group (OR1.32[CI 95%,1.07,2.88]) was
more likely to be adherent versus control. Mean persistence with antihyperten-
sives in the intervention was 291-days versus 257-days for control. No significant
difference in persistence seen between intervention and control. CONCLUSIONS:
This RCT showed improved adherence to statin and antihypertensive medications
among the intervention cohort. Findings from this studywould be useful in guiding
ongoing efforts to optimize cardiovascular-drug adherence targeted toward unin-
sured working-adults.
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OBJECTIVES: This study examined stroke risk and prevention among US patients
diagnosed with atrial fibrillation (AF).METHODS: Data were extracted from the US
2010 National Health and Wellness Survey, an annual, Internet-based, cross-sec-
tional database of 75,000 adults (age18). Stroke risk was assessedwith CHADS2,
determined by presence of congestive heart failure, hypertension, diabetes melli-
tus, old age (75 years), and history of stroke or transient ischemic attack. Low-
(CHADS2  0), moderate- (1), and high- (2) risk patients reported which steps, if
any, they took to prevent stroke: low fat or low sodium diet, regular exercise,
smoking cessation, weight loss, blood pressure or cholesterol reduction, or use of
baby aspirin, aggrenox, warfarin, clopidogrel, or other medications. High-risk pa-
tients were compared with low and moderate-risk patients, adjusting for socio-
demographic and health characteristics using logistic regression models.
RESULTS:Among 1,350 respondents diagnosedwithAF (projectedUSprevalence of
1.49%), 308 (22.8%) were low, 473 (35%) moderate, and 569 (42.2%) high in risk of
stroke. High- vs. low-risk patients were significantly more likely to take any pre-
ventative steps (60.5% vs. 34.1%, respectively; OR2.75, p0.001). Furthermore,
high-risk patients were significantly more likely to take steps to lower their blood
pressure (OR8.33, p0.001), cholesterol (OR2.46, p0.007), use clopidogrel
(OR7.46, p0.027) or other stroke-prophylactic medications (OR3.32, p0.003)
compared with low-risk patients. No differences were observed on lifestyle modi-
fication such as diet, exercise or smoking cessation. CONCLUSIONS: These results
suggest, US adults at high risk of stroke are more likely to take steps to lower high
blood pressure and cholesterol, and to use medications to prevent stroke, com-
paredwith low-risk individuals. No significant differences emerged on diet, regular
exercise, smoking cessation and aspirin use. Higher risk correlated with higher
prevention, yet there remains an unmet need for increased targeted treatment and
lifestyle changes for high-risk AF patients.
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OBJECTIVES: To assess themeasurement properties and validity of Health Utilities
Index Mark 3 (HUI3) Japanese version for stroke patients in Japan.METHODS: The
HUI3 was administered 553 patients with stroke who were admitted in seven hos-
pitals. Proxies of the patients completed Japanese version of the HUI3 question-
naires at start phase of rehabilitation. Patients were categorized using modified
Rankin scale (MRS). The construct validity was assessed by analyzing the degree to
which lower score on the HUI3 scores correlated positively with MRS. RESULTS:
Mean global score was as follows: MRS 10.62 (SD0.22), MRS 20.48 (SD0.28),
MRS 30.27 (SD0.24), MRS 40.00 (SD0.18), MRS 5 0.23 (SD0.11). Worst
mean single score was ambulation (0.29) and, subsequently cognition (0.49), and
dexterity (0.58). CONCLUSIONS: Our results indicate the productive future for Jap-
anese HUI3 use and showed precise measuring properties of the HUI3 Japanese
version in assessing health status for stroke patients.
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